Healthcare Industry News: SINGULAIR
News Release - August 11, 2009
David Esposito Joins Phadia as Senior Vice President of U.S. Sales and MarketingPORTAGE, Mich.--(HSMN NewsFeed)--Phadia AB, the world leader in in vitro allergy diagnostic testing and maker of ImmunoCAP(R) Specific IgE blood test, today announced that David Esposito has joined the company as Senior Vice President of U.S. Sales and Marketing.
Mr. Esposito joins Phadia after a successful 16 year career at Merck, during which time he rose from field sales representative to become Executive Director for the Respiratory Marketing Team. At Merck, Esposito led the marketing efforts towards physicians in the US for SINGULAIR(R), a leading drug used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Under his guidance the drug achieved blockbuster status with sales exceeding $3 billion.
At Phadia, Mr. Esposito will lead the continued marketing and sales growth initiatives in the United States, continue to expand the company’s professional sales team, and expand the marketing efforts to drive awareness for the company’s ImmunoCAP Specific IgE blood test, which helps primary care physicians diagnose atopic triggers underlying their patients’ asthma, rhinitis and eczema.
Magnus Lundberg, Chief Executive Officer of Phadia AB, said, “David Esposito is a talented pharmaceutical sales and marketing executive who brings abundant experience, skill and knowledge to Phadia. His proven track record in overseeing the marketing efforts for one of the most widely-used drugs for allergy and asthma is a perfect fit with Phadia, as he knows our audience and has driven measurable sales results in that arena. Phadia faces a significant growth opportunity, and we are excited to have David Esposito leading our U.S. sales and marketing team.”
Mr. Esposito added, “I am grateful to join Phadia at a time when its opportunity to expand in the U.S. has never been greater. The U.S. market remains underpenetrated for serum-based allergy testing which provides primary care physicians, who see the vast majority of patients in the US with asthma and rhinitis, access to important, additional diagnostic information. ImmunoCAP(R) results allow improved diagnosis of patients suffering from allergy-like symptoms. By growing the awareness of ImmunoCAP(R), the world’s leading diagnostic tool for in vitro allergy testing, through the further expansion of our ongoing sales and marketing initiatives, I believe we can increase the already tremendous US growth. I look forward to executing on our plan and extending the company’s track record of double-digit revenue growth in the United States.”
Mr. Esposito graduated with a B.S. Degree in Civil Engineering from the United States Military Academy, West Point, NY in 1990 and received his MBA from Syracuse University in 1998. Upon graduation from West Point, Esposito was commissioned a 2nd Lieutenant in the US Army Infantry and earned Ranger, Airborne and Air Assault designations. In 1991, while serving in Operation Desert Shield/Storm, he was awarded the Bronze Star for combat action in Iraq as a rifle platoon leader in the US Army’s elite 101st Airborne Division (Air Assault).
Phadia AB, headquartered in Uppsala, Sweden, is the world leader in in vitro IgE diagnostic research and product development. Its US affiliate, Phadia US Inc is in Portage, Michigan. For more information, contact their Customer Service at 800.346.4364.
For more information on Phadia or ImmunoCAP, please visit http://www.isitallergy.com/.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.